Published by
@ShahidNShah
@ShahidNShah
The 3rd Liquid Biopsy Surveillance Summit is held on 21-22 November 2024 in Boston, MA.Liquid biopsies are revolutionizing clinical trials, emerging as a game-changing diagnostic tool for monitoring molecular residual disease and detecting disease resistance. This breakthrough enables precise patient stratification, ensuring they receive the most effective and safe treatments. In 2024, a wave of collaborations has surged, propelling the use of liquid biopsies for MRD testing to new heights. The FDA's recognition of MRD as an endpoint in multiple myeloma marks a monumental leap forward for the field, heralding a new era in patient care and therapeutic development.The 3rd Liquid Biopsy Surveillance Summit returns as the leading East Coast forum solely dedicated to MRD detection in clinical trials to improve stage response monitoring to get patients earlier access to precision treatments.
[Read on liquid-biopsy-surveillance-summit.com](https://liquid-biopsy-surveillance-summit.com/take-part/register/)
Continue reading at liquid-biopsy-surveillance-summit.com
November 21 to November 25, 2024
Centro Cultural de Belem, Praca do Imperio, Lisboa, 1449-003, Portugal
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Oct 18, 2024 at 5:37am